- Acquired by Leap Therapeutics, Jan 2017
- Raised $35M Series A led by Rainfall Ventures, Apr 2012
- Raised $13M Seed round led by Viola Growth, Mar 2011
About
MacroCure Ltd is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. The company's approach is to treat chronic and other hard-to-heal wounds by injecting the human body's own wound-healing and regenerative components directly into the wound. MacroCure's lead product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell's two phase 3 double-blind clinical trials target a broad indication for the treatment of diabetic foot ulcers and venous leg ulcers. MacroCure already has product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds. CureXcell has effectively treated more than 5,000 patients in commercial or clinical study settings in Israel. In 2017, MacroCure Ltd merged into Leap Therapeutics, Inc.
Funding history · 3 rounds · $48.0M total
Headcount over time
Q&A
- What is MacroCure's primary focus?
- MacroCure is a clinical-stage biopharmaceutical company focused on developing a therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers.
- What is MacroCure's lead product candidate?
- MacroCure's lead product candidate is CureXcell, a combination of living human white blood cells activated to facilitate healing and stimulate wound closure.
- What is the current status of MacroCure?
- MacroCure was acquired by Leap Therapeutics in January 2017 and is currently inactive.
- When was MacroCure founded?
- MacroCure was founded in January 2008.
- What was the total amount of funding raised by MacroCure?
- MacroCure raised a total of $102,000,000 USD.
- Which investors participated in MacroCure's April 2011 funding round?
- In April 2011, MacroCure raised $13,000,000 USD from investors including Viola Growth.
- Which investors participated in MacroCure's May 2012 funding round?
- In May 2012, MacroCure raised $35,000,000 USD from investors including Rainfall Ventures.
- What is the status of CureXcell's clinical trials?
- CureXcell has undergone two phase 3 double-blind clinical trials targeting diabetic foot ulcers and venous leg ulcers. It also has product approval as a medical device in Israel for chronic and hard-to-heal wounds.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | macrocure.com |
|---|---|
| linkedin.com/company/566839 | |
| YouTube | youtube.com/channel/UCcAHngMbpAgoQAGsa5A_zXQ |
Identifiers & details
| Legal name | Macrocure Ltd. |
|---|---|
| Former names | Leap Therapeutics |
| Founded | 2008-1 |
| Employees (exact) | 9 |
| Offices | USA |
| Status reason | Acquired (Inactive) by Leap Therapeutics on Jan 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Leap Therapeutics 2017-01
Radar intelligence
Patents
| EPO | 6 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | macrocure.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514083765 |
|---|---|
| Status | מחוסלת מרצון — CLOSED |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-01-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2017 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הסיבים 25 פתח תקווה |